Bicycle to receive a $50M up front, ~$1.7B in development & commercial-based milestones along with royalties on Bicycle-based therapies commercialized by Novartis. Novartis will lead the further development, manufacture & commercialization of the BRCs & will fund all pre-clinical & clinical development & commercialization activities
The collaboration enables Bicycle to discover and develop new cutting-edge radiopharmaceutical cancer treatments based on Bicycles to be developed into BRCs using its phage platform
Bicycle’s BT5528, a BTC targeting EphA2; BT8009, a BTC targeting Nectin-4 & a well-validated tumor Ag; and BT7480, a Bicycle TICA targeting Nectin-4 & agonizing CD137 while BT1718 is being studied in P-I/IIa trial
Ref: Businesswire | Image: Bicycle
Related News:- Bicycle Therapeutics Signs Clinical Development Partnership with Cancer Research UK for BT7401
